Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to $145.0 million.

  • BIO-TECHNE's Cash & Equivalents fell 22.70% to $145.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.0 million, marking a year-over-year decrease of 22.70%. This contributed to the annual value of $162.2 million for FY2025, which is 6.85% up from last year.
  • Per BIO-TECHNE's latest filing, its Cash & Equivalents stood at $145.0 million for Q3 2025, which was down 10.62% from $162.2 million recorded in Q2 2025.
  • BIO-TECHNE's Cash & Equivalents' 5-year high stood at $211.8 million during Q4 2021, with a 5-year trough of $127.3 million in Q1 2023.
  • In the last 3 years, BIO-TECHNE's Cash & Equivalents had a median value of $148.7 million in 2023 and averaged $153.8 million.
  • In the last 5 years, BIO-TECHNE's Cash & Equivalents surged by 36.44% in 2024 and then fell by 22.70% in 2025.
  • BIO-TECHNE's Cash & Equivalents (Quarterly) stood at $211.8 million in 2021, then dropped by 22.26% to $164.7 million in 2022, then decreased by 20.98% to $130.1 million in 2023, then soared by 36.44% to $177.5 million in 2024, then fell by 22.70% to $145.0 million in 2025.
  • Its Cash & Equivalents was $145.0 million in Q3 2025, compared to $162.2 million in Q2 2025 and $140.7 million in Q1 2025.